Bladder Carcinoma in Situ (CIS): Diagnosis and Treatment
Quick answer
CIS is a flat, high-grade cancer lesion in the bladder lining, also called Tis. Not having invaded the muscle does not make it benign or unimportant. Diagnosis, risk assessment and treatment planning should be discussed with the urology team.
Is CIS the same as a raised bladder tumour?
A papillary tumour may project into the bladder cavity, whereas CIS lies flat along the surface. CIS can occur alone, accompany a papillary tumour or be detected during follow-up. The size of the visible mass in the operation report therefore does not provide all the information about associated CIS.
References for this section: Cancer Research UK. Types of bladder cancer. EAU. Non-muscle-invasive Bladder Cancer: Pathological Staging and Classification Systems.
Why treat CIS if it is stage zero?
Stage describes the tissue layer involved and spread, while grade describes cell features. CIS is high grade. Tis or stage 0is does not mean there is no cancer. The code alone cannot calculate an individual's progression risk; associated tumours, previous treatment and other findings also matter.
References for this section: National Cancer Institute. Bladder Cancer Stages.
Does a normal ultrasound rule out CIS?
No. Flat lesions can be missed on imaging or by their appearance at standard cystoscopy. Biopsy and pathological examination of suspicious areas are important for diagnosis. Urine cytology provides supporting information but does not complete the assessment by itself. Findings are considered together when choosing biopsy sites and deciding whether additional visualisation techniques are needed.
How do urinary symptoms, cytology and biopsy complement each other?
Persistent urgency and burning can occur with CIS, but also with infection and other benign conditions. Symptoms alone cannot diagnose CIS. Culture looks for microorganisms, cytology examines shed cells and biopsy shows tissue architecture. These tests answer different questions, so their findings need not all be normal or abnormal together.
Cystoscopy may show a non-specific change such as redness when CIS is suspected. Biopsy helps determine what that appearance represents. Techniques such as blue-light photodynamic diagnosis may help select areas in appropriate circumstances. They need not be available in every centre or used in every patient; not using one does not by itself prove the diagnosis was wrong.
References for this section: EAU. Non-muscle-invasive Bladder Cancer: Diagnosis — TURBT, second resection and pathology report. National Cancer Institute. Bladder Cancer Diagnosis.
What do primary, concomitant and later CIS mean?
Primary CIS is diagnosed without a papillary tumour. Concomitant CIS occurs alongside a papillary tumour. CIS found after an earlier papillary tumour represents a different disease history. These distinctions show why the same word “CIS” does not mean identical treatment for everyone. Keep previous reports with the new one.
The randomised EORTC trial by de Reijke and colleagues included different CIS groups and compared BCG with epirubicin. Response was assessed using findings such as biopsy and cytology, rather than disappearance of symptoms alone. Response at the first check and long-term disease control are different outcomes.
If cytology is positive but no bladder mass is seen, is assessment complete?
No. High-grade cells may come from the upper urinary tract or, in men, other urothelial sites such as the prostatic urethra. Findings may prompt further bladder sampling, upper-tract assessment or prostatic urethral biopsy. These are not required in the same order for everyone; prior results and risk guide the investigation.
The CIS study by Solsona and colleagues provides evidence on why disease at urothelial sites outside the bladder deserves separate assessment. Involvement rates from an older, selected series cannot be transferred to every newly diagnosed patient. The practical aim is to avoid interpreting an unexplained abnormal result only through the visible bladder surface.
References for this section: Solsona E, Iborra I, Ricós JV, et al. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol. 1996;155(3):895-9; discussion 899-900. EAU. Non-muscle-invasive Bladder Cancer: Follow-up of Patients with NMIBC.
What should be discussed at the first consultation after CIS is diagnosed?
- Whether pathology confirms the diagnosis and whether a Ta or T1 tumour is also present.
- Any previous bladder tumour, BCG or other intravesical treatment.
- The aim of the proposed treatment, alternatives and follow-up plan.
- Whether pathology review is needed when results do not agree.
BCG or bladder removal?
Treatment is not the same for everyone. Intravesical BCG is an important option for suitable patients. Other risk features or persistent disease despite previous adequate BCG may require discussion of more extensive treatments. The wish to preserve the bladder, progression risk and effects of surgery should be discussed together. This article does not select BCG or surgery for an individual.
References for this section: EAU. Non-muscle-invasive Bladder Cancer: Disease Management.
Is having no symptoms after treatment enough?
Burning or bleeding resolving does not, by itself, prove a treatment response. Find out when follow-up cystoscopy and necessary tests are due. Keeping reports, treatment dates and previous results helps later consultations bring the findings together. Ask for clarification if the written follow-up plan is unclear.
How is bladder-preserving treatment success assessed?
A clear first check is favourable, but does not guarantee permanent disease control. In the long-term EORTC study by Jakse and colleagues, recurrence and progression were observed after initial response. Follow-up therefore remains part of treatment even when BCG has preserved the bladder. One successful cystoscopy does not remove all subsequent assessments.
If CIS persists, the amount of BCG received and the timing of assessment matter. With very-high-risk features or BCG-unresponsive disease, discuss the benefits and consequences of bladder removal without delay. Alongside understanding a preference for preservation, it is important to agree in advance which findings would require a change of treatment.
References for this section: Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol. 2001;40(2):144-50. EAU. Non-muscle-invasive Bladder Cancer: Disease Management.
Which written plan should I leave the consultation with?
- Where CIS was confirmed and whether Ta/T1 or other risk features accompany it.
- When treatment starts, how response will be assessed and when results will be discussed.
- Which findings would prompt a treatment change if disease persists.
- Whom to contact for new bleeding, fever or inability to pass urine.
If seeking another opinion, share previous pathology and all intravesical treatment dates rather than only a photograph of the latest report. This distinguishes a new diagnosis from disease persisting despite previous treatment. An online CIS heading cannot make that distinction for you.
Frequently asked questions
Is CIS a precancerous condition?
Bladder CIS is a high-grade, non-invasive cancer lesion. It should not be equated with a benign change; diagnosis and treatment need to be discussed.
Does CIS always require bladder removal?
That word alone does not determine the decision. Bladder-preserving or surgical options are discussed according to associated risks, previous treatment and the person's circumstances.
Can Ta and CIS both appear in a pathology report?
Yes. A papillary tumour and flat CIS can coexist. Both findings are considered when assessing treatment.
Sources
- EAU. Non-muscle-invasive Bladder Cancer: Pathological Staging and Classification Systems [Internet]. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/pathological-staging-and-classification-systems
- National Cancer Institute. Bladder Cancer Stages [Internet]. Available from: https://www.cancer.gov/types/bladder/stages
- Cancer Research UK. Types of bladder cancer [Internet]. Available from: https://www.cancerresearchuk.org/about-cancer/bladder-cancer/types-stages-grades/types
- EAU. Non-muscle-invasive Bladder Cancer: Disease Management [Internet]. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/disease-management
- EAU. Non-muscle-invasive Bladder Cancer: Diagnosis — TURBT, second resection and pathology report [Internet]. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/diagnosis
- National Cancer Institute. Bladder Cancer Diagnosis [Internet]. Available from: https://www.cancer.gov/types/bladder/diagnosis
- EAU. Non-muscle-invasive Bladder Cancer: Follow-up of Patients with NMIBC [Internet]. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/followup-of-patients-with-nmibc
- Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). J Urol. 2005;173(2):405-9. doi:10.1097/01.ju.0000150425.09317.67 · PubMed
- Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol. 2001;40(2):144-50. doi:10.1159/000049765 · PubMed
- Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol. 1996;155(3):895-9; discussion 899-900. doi:10.1016/s0022-5347(01)66338-9 · PubMed
Keep reading:
Related patient guides
Bladder Cancer Pathology Report: What Do Ta, T1, CIS and High Grade Mean?
Understand Ta, T1, CIS, low grade, high grade and muscle sampling in a bladder tumour report, and how stage differs from grade.
BCG Treatment for Bladder Cancer: What Happens, Side Effects and Warning Signs
Who may receive intravesical BCG, how is it given and how long does it last? Understand side effects, reasons to postpone treatment and urgent warning signs.
Negative or Atypical Urine Cytology: How Should Results Be Interpreted?
Does urine cytology rule out cancer? Understand negative, atypical and suspicious findings and how they relate to culture, cystoscopy and other urine tests.